新京报讯 ...

KHN702片是公司自主研发的高选择性NaV1.8抑制剂，是一种新型的非阿片类镇痛药物，无成瘾性，属于化药1类创新药。前期已完成的研究结果显示KHN702片安全性较好，且在多种疼痛模型中具有良好的治疗作用，预期临床应用前景较好。

【康弘药业：KHN702片获得药物临床试验批准通知书】财联社3月24日电，康弘药业(002773.SZ)公告称，公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意KHN702片开展临床试验。该药品为自主研发的高选择性NaV1.8抑制剂，属于化药1类创新药，预期临床应用前景较好。但药品研发具有不确定性，投资者需谨慎决策。 “特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰 ...

FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...

Latigo Biotherapeutics，一家专注于非阿片类止痛药研发的创新型公司，近日完成了B轮融资。此轮融资由5AM Ventures、Access ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs. | Latigo Biotherapeutics has whipped together a $150 ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

The Elder Scrolls 6 is currently in development, but despite some recent small updates, it's likely to still be some time until we see it arrive. Recently, we learned that Bethesda has launched a ...

Network pharmacology results suggest that voltage-gated sodium channel subtypes (Nav1.1, Nav1.2, and Nav1.6) may be the targets for RC prevention of DE. Furthermore, the Western blot analysis revealed ...

Here’s how it works. Here's what we know about The Elder Scrolls 6 so far, including a look at platforms we can expect it to launch on. Hopefully, we will hear more about the game by the end of ...

Body Dimensions 169.9 x 77.2 x 9.7 mm (6.69 x 3.04 x 0.38 in) ...

Now the time has finally come: Bluetooth 6.0 is just around the corner. Read on to find out what’s in it for you and what capabilities the developers have given the new wireless standard.